Odyssean LLC Invests $3.06 Million in BridgeBio Pharma, Inc. $BBIO

Key Points

• Odyssean LLC acquired 41,015 BridgeBio Pharma shares during the second quarter, worth approximately $3.06 million. Institutional investors collectively own 99.85% of the company.
• BridgeBio reported quarterly revenue of $243.68 million, up 120.4% year over year, but its adjusted loss of $0.78 per share missed analyst expectations of a $0.58 loss.
• Analyst sentiment remains broadly positive, with 20 Buy ratings and a consensus “Moderate Buy” rating alongside a $101.53 price target. However, insiders sold approximately $27.6 million of stock over the past quarter.

Odyssean LLC acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 41,015 shares of the company's stock, valued at approximately $3,055,000.

Other institutional investors have also made changes to their positions in the company. Silvant Capital Management LLC acquired a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $28,000. Allworth Financial LP bought a new stake in BridgeBio Pharma during the second quarter worth approximately $31,000. Harvest Fund Management Co. Ltd acquired a new position in BridgeBio Pharma during the third quarter valued at approximately $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the first quarter valued at approximately $35,000. Finally, Farther Finance Advisors LLC raised its position in shares of BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock valued at $39,000 after purchasing an additional 245 shares during the period. 99.85% of the stock is owned by institutional investors.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, Director Andrea Ellis sold 17,167 shares of the firm's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $84.00, for a total value of $1,442,028.00. Following the sale, the director directly owned 22,579 shares in the company, valued at $1,896,636. This trade represents a 43.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the firm's stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total transaction of $160,120.00. Following the completion of the sale, the chief accounting officer owned 127,401 shares in the company, valued at $10,199,724.06. This represents a 1.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 347,343 shares of company stock worth $27,591,000. 14.23% of the stock is currently owned by insiders.

BridgeBio Pharma Stock Down 0.8%

Shares of BBIO stock opened at $74.84 on Friday. BridgeBio Pharma, Inc. has a 12 month low of $48.78 and a 12 month high of $93.42. The firm has a market cap of $14.63 billion, a PE ratio of -20.96 and a beta of 0.97. The stock has a 50 day moving average of $80.74 and a 200-day moving average of $73.62.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The firm had revenue of $243.68 million for the quarter, compared to analyst estimates of $220.91 million. During the same quarter last year, the firm posted ($0.95) EPS. The company's revenue was up 120.4% compared to the same quarter last year. As a group, equities analysts predict that BridgeBio Pharma, Inc. will post -2.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on BBIO shares. UBS Group restated a "buy" rating on shares of BridgeBio Pharma in a research note on Wednesday. Morgan Stanley lowered their target price on shares of BridgeBio Pharma from $98.00 to $97.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 11th. Piper Sandler lifted their target price on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the stock an "overweight" rating in a report on Tuesday, August 11th. Weiss Ratings lowered shares of BridgeBio Pharma from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Finally, HC Wainwright restated a "buy" rating and set a $120.00 price target on shares of BridgeBio Pharma in a report on Wednesday. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BridgeBio Pharma currently has a consensus rating of "Moderate Buy" and a consensus price target of $101.53.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target, indicating that the analyst believes BridgeBio’s longer-term growth potential remains intact despite the earnings-estimate reductions. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma
• Positive Sentiment: Barclays and Cantor Fitzgerald also maintained Buy ratings on BridgeBio Pharma, providing additional analyst support for the stock. Barclays Sticks to Its Buy Rating for BridgeBio Pharma Cantor Fitzgerald Remains a Buy on BridgeBio Pharma
• Neutral Sentiment: HC Wainwright’s estimates still imply a transition from losses in 2026 to profitability in 2027, forecasting a $1.88 per-share loss for fiscal 2026 and $1.31 in earnings for fiscal 2027.
• Negative Sentiment: HC Wainwright lowered its fiscal 2026 EPS forecast to a $1.88 loss from a $1.50 loss and cut its fiscal 2027 estimate to $1.31 from $2.19. It also reduced estimates for several 2027 quarters, including Q1 to a $0.18 loss from $0.11 in earnings and Q2 to $0.19 in earnings from $0.44.
• Negative Sentiment: The estimate cuts extend to near-term results: Q3 2026 EPS was lowered to a $0.40 loss from a $0.38 loss, while Q4 2026 EPS was trimmed slightly to $0.13 from $0.14. These revisions may weigh on sentiment because they point to slower-than-previously-expected earnings progression.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source